WINT vs CRVS vs TPVG vs CRL vs JPM

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 1x trailing P/E (5. 3x forward), making it the more compelling value choice. Analysts rate Corvus Pharmaceuticals, Inc. (CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 1x versus JPMorgan Chase & Co. at 16. 2x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 5. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus TriplePoint Venture Growth BDC Corp. 's 5. 28x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +336. 3%, compared to -100. 0% for Windtree Therapeutics, Inc. (WINT). Over 10 years, the gap is even starker: JPM returned +481. 2% versus WINT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 70β versus Corvus Pharmaceuticals, Inc. 's 1. 90β — meaning CRVS is approximately 173% more volatile than TPVG relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Windtree Therapeutics, Inc. grew EPS 97. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -444. 5% for Windtree Therapeutics, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -372. 2% for WINT. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus TriplePoint Venture Growth BDC Corp. 's 5. 28x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 5. 3x forward P/E versus 16. 7x for Charles River Laboratories International, Inc. — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRVS: 178. 5% to $33. 17.

In this comparison, WINT (100.

0% yield), TPVG (20. 5% yield), JPM (1. 8% yield) pay a dividend. CRVS, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, CRVS: -7. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WINT (Healthcare) and CRVS (Healthcare) and TPVG (Financial Services) and CRL (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WINT is a small-cap income-oriented stock; CRVS is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; CRL is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. WINT, TPVG, JPM pay a dividend while CRVS, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.